165 related articles for article (PubMed ID: 36348973)
1. Sex-specific biomarkers in Alzheimer's disease progression: Framingham Heart Study.
Liu C; Li Y; Nwosu A; Ang TFA; Liu Y; Devine S; Au R; Doraiswamy PM
Alzheimers Dement (Amst); 2022; 14(1):e12369. PubMed ID: 36348973
[TBL] [Abstract][Full Text] [Related]
2. Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study.
Ding H; Li Y; Ang TFA; Liu Y; Devine S; Au R; Doraiswamy PM; Liu C
J Prev Alzheimers Dis; 2023; 10(3):530-535. PubMed ID: 37357294
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.
Tsiknia AA; Edland SD; Sundermann EE; Reas ET; Brewer JB; Galasko D; Banks SJ;
Mol Psychiatry; 2022 Oct; 27(10):4314-4322. PubMed ID: 35768637
[TBL] [Abstract][Full Text] [Related]
5. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
[TBL] [Abstract][Full Text] [Related]
7. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.
Pase MP; Beiser AS; Himali JJ; Satizabal CL; Aparicio HJ; DeCarli C; Chêne G; Dufouil C; Seshadri S
JAMA Neurol; 2019 May; 76(5):598-606. PubMed ID: 30830207
[TBL] [Abstract][Full Text] [Related]
9. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
Wei H; Kong M; Zhang C; Guan L; Ba M;
Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
11. Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP) cohort.
Gu Y; Honig LS; Kang MS; Bahl A; Sanchez D; Reyes-Dumeyer D; Manly JJ; Dage JL; Lantigua RA; Brickman AM; Vardarajan BN; Mayeux R
Alzheimers Dement; 2024 Mar; 20(3):1988-1999. PubMed ID: 38183363
[TBL] [Abstract][Full Text] [Related]
12. Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study.
Wang YL; Chen J; Du ZL; Weng H; Zhang Y; Li R; Jia Z; Sun M; Jiang J; Wang FZ; Xu J;
Front Neurol; 2021; 12():695696. PubMed ID: 34557143
[No Abstract] [Full Text] [Related]
13. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
14. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
[TBL] [Abstract][Full Text] [Related]
16. Sex and Education Modify the Association Between Subjective Cognitive Decline and Amyloid Pathology.
Bolton CJ; Khan OA; Liu D; Wilhoite S; Dumitrescu L; Peterson A; Blennow K; Zetterberg H; Hohman TJ; Jefferson AL; Gifford KA
medRxiv; 2023 Nov; ():. PubMed ID: 37961115
[TBL] [Abstract][Full Text] [Related]
17. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
18. Peripheral inflammatory biomarkers are associated with cognitive function and dementia: Framingham Heart Study Offspring cohort.
Chen J; Doyle MF; Fang Y; Mez J; Crane PK; Scollard P; ; Satizabal CL; Alosco ML; Qiu WQ; Murabito JM; Lunetta KL
Aging Cell; 2023 Oct; 22(10):e13955. PubMed ID: 37584418
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
